Welcome to the Cellumen Newsroom
View Recent Press Releases, Publications and News Articles
Recent Press Releases
Cellumen Assets Acquired by Apredica
(4 Aug 2010)
The assets of Cellumen were acquired by Apredica, an ADME Tox contract research organization, and added to Apredica's High Content Toxicology program.
Cellumen Finds Increased Predictivity for Human DILI Through Rat Hepatocyte Panel
(5 Nov 2009)
Cellumen announces a less expensive, more reliable rodent panel that offers increased predictivity for human drug induced liver injury (DILI) than other options currently available.
Cellumen Enters Second Phase of Safety Assessment Testing for EPA ToxCast Program
(21 Jul 2009)
Cellumen has been selected by the EPA to provide its CellCiphr analysis in the second phase of the U.S. Environmental Protection Agency’s (EPA) ToxCast™ program. Cellumen successfully completed their first phase in the ToxCast program, generating hepatic toxicity profiles that served as key features of predictive toxicity models. The EPA ToxCast Program is a cost-effective approach for prioritizing the toxicity testing of large numbers of chemicals in a short time-frame.
Cellumen Launches Rat Cardiomyocyte Early Safety Assessment Panel, Signs Contract with International Biotech Company
(8 Jul 2009)
Cellumen announces that it has added a Rat Cardiomyocyte Panel to its CellCiphr® Early Safety Assessment services that identifies toxic compounds and their corresponding mechanisms of toxicity earlier in the drug development process. Cellumen also announces that the company has successfully completed two recent customer contracts.
Recent News Articles
Pittsburgh Business Times
(November 13, 2009)
The Pittsburgh Business Times reports on Cellumen’s reliable rodent panel that offers increased predictivity for drug induced liver toxicity and discusses the impact of this panel on the company's growth in 2010.
BioWorld Today Editors publish Cellumen's article entitled 'Early Safety Assessment Can Enhance Pipeline Value and Increase Profitability." The news article was written by Donald P. Taylor, Senior Director of Marketing and Corporate Development. He defines how a biotech company can enhance the value of its clinical pipeline at the start of the hit-to-lead phase by more than $4 million when they apply appropriate early safety assessment procedures, and he describes the present value of margin dollars created by Cellumen's powerful CellCiphr safety assessment solutions.
Drug Discovery & Development
(March 2, 2009)
Drug Discovery & Development Editors profile Cellumen's predictive power of in vitro toxicity testing using Cellular Systems Biology in an article by D. Lansing Taylor, Ph.D., entitled Human vs. Rodent.
(February 19, 2009)
Bio-IT World Editors highlight Cellumen's unique approach of using Cellular Systems Biology to rapidly identify promising drug candidates and red-flag tox-causing compounds early in the drug discovery process.
View all News Articles»